Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| The opioids market was estimated to be worth $9.6 billion |
 |
 |
 |
|
The opioids market was estimated to be worth $9.6 billion across the seven major pharmaceutical markets (7MM) in 2008, and strong historical sales means it could reach $11.9 billion by 2018.
The launch of several branded products are expected to be the main growth drivers with long-acting and short and rapid-acting opioids forecasted to be the most dynamic over 2009 - 2018. However, the number and diversity of products in late-stage development could limit the commercial potential of individual brands, with the market seeing significant saturation and price competition. Even so, the conventional opioids market still represents a large volume of prescriptions and with several new products on the horizon such as Tapentadol (Johnson & Johnson) and Acurox (King Pharmaceuticals), it possesses growth potential.
A strategic analysis of the likely impact recent events will have on the future opioids market.
|
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis